Bioventix Plc Appointment of CFO

 
TIDMBVXP 
 
Bioventix plc 
                        ("Bioventix" or the "Company") 
 
                              Appointment of CFO 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that Bruce Hiscock will join the Board as Chief 
Financial Officer with immediate effect. 
 
Mr Hiscock was previously CEO and CFO of everyLIFE Technologies, a technology 
business delivering digital care planning solutions to social care providers. 
Prior to this he was the Managing Director of MITIE Security Systems, the CEO 
of Protec plc, an AIM listed security and technology services business, and 
held several CFO roles at both fast-growing listed and private companies over a 
30-year career. Mr Hiscock is a member of the Institute of Chartered 
Accountants of Scotland. 
 
The following information regarding the appointment of Bruce Edward Heath 
Hiscock (aged 61) is required to be disclosed under Schedule 2(g) of the AIM 
Rules for Companies: 
 
Current directorships and/or          Former directorships and/or 
partnerships                          partnerships 
                                      (within the last five years) 
 
n/a                                   everyLIFE Technologies Limited 
                                      Warnborough Associates Limited 
 
There are no further disclosures to be made under Schedule 2(g) of the AIM 
Rules for Companies. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: [phone] 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: [phone] 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 

(END) Dow Jones Newswires

July 01, 2020 02:00 ET (06:00 GMT)